Safety analysis of the BCL-2 inhibitor venetoclax for CLL
Myeloma 2016: Panel discussion on the status of genomics
Chng Wee Joo et al.
Venetoclax and ibrutinib and drug combinations for CLL
Results of trial of venetoclax with bendamustine/rituximab or bendamustine/obinutuzumab in CLL
Novel therapies in myeloma: selinexor, venetoclax, among others
Heinz Ludwig et al.